{"id":"W2592892140","doi":"10.1182/blood.v116.21.lba-6.lba-6","title":"A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dasatinib; Internal medicine; Clinical endpoint; Imatinib; Imatinib mesylate; Randomized controlled trial; Gastroenterology; Nilotinib; Myeloid leukemia; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003039807,0.0008375531,0.002901199,0.0006061143,0.0001659954,0.00005810443,0.0007606432,0.0005864452,0.001494422],"category_scores_gemma":[0.00314308,0.0006028276,0.0008704714,0.0009397339,0.0006740759,0.0002653637,0.0003061941,0.001848549,0.00005644018],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003512717,"about_ca_system_score_gemma":0.008119891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002439914,"about_ca_topic_score_gemma":0.004782178,"domain_scores_codex":[0.9932855,0.0008369422,0.002761259,0.001032176,0.0009296178,0.001154546],"domain_scores_gemma":[0.9945042,0.002270613,0.001028387,0.001750617,0.0001181283,0.0003280566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9193755,0.01199709,0.00003435706,0.0002261112,0.0006826964,0.0003875676,0.002418818,0.00002143355,0.04675108,0.0001468853,0.0003692754,0.01758919],"study_design_scores_gemma":[0.9595672,0.01569699,0.00005041804,0.0006613124,0.001195775,0.0000815226,0.0001204226,0.003292745,0.01717754,0.0001319475,0.001547136,0.0004769125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834743,0.001110347,0.00002846445,0.0005559653,0.001429794,0.01193354,0.00009574399,0.0001251361,0.00124676],"genre_scores_gemma":[0.992888,0.0005435379,0.0003772906,0.000156105,0.002598132,0.002538253,0.0003070229,0.0001299439,0.0004616699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04019178,"threshold_uncertainty_score":0.9996423,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01886127065958134,"score_gpt":0.3201389173556108,"score_spread":0.3012776466960295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}